COVID-19 Hypercoagulation as a Result of Cancer Metabolism

The Hypercoagulation Being Observed in COVID-19 Is Due to the Virus’ Induction of Metatastic Cancer’s Cellular Processes

This is precisely what happens in COVID-19 – as well as metatastic cancer: Mechanisms for cancer-induced hypercoagulation and consequential D-dimer formation. Cancer cells promote a hypercoagulable status and activate the hemostatic system. The cancer cells induce the hypercoagulable status by cell-to-cell interaction with endothelial cells, direct release of TF and CP, production of cytokines such as IL-1and TNF and activation of monocyte, macrophage, and platelet. CP ¼ cancer procoagulants, IL-1: interleukin-1, PAI: plasminogen activator inhibitor, TF: tissue factor, TNF: tumor necrosis factor. 

Referenced/Related Papers

The right place for IL-1 inhibition in COVID-19

D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy